Pharmaceutical Formulation Containing Gelling Agent
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
1 - 40 . (canceled)
41 . A therapeutic pharmaceutical composition comprising: a mixture including (a) a water soluble drug susceptible to abuse; (b) a gel-forming polymer; (c) a disintegrant; and (d) a surfactant; wherein the pharmaceutical composition exhibits an immediate release profile.
42 . The therapeutic pharmaceutical composition of claim 41 , wherein the pharmaceutical composition is in unit dose form.
43 . The therapeutic pharmaceutical composition of claim 41 , wherein the pharmaceutical composition is in suppository, capsule, pill, soft gelatin capsule, or compressed tablet form.
44 . The therapeutic pharmaceutical composition of claim 41 , wherein the water soluble drug susceptible to abuse is present in an amount of 2.3 to 29.8 wt % of the composition.
45 . The therapeutic pharmaceutical composition of claim 41 , wherein the disintegrant is present in an amount of 5 to 15 wt % of the composition.
46 . The therapeutic pharmaceutical composition of claim 41 , wherein the surfactant is present in an amount of 1 to 10 wt % of the composition.
47 . The therapeutic pharmaceutical composition of claim 41 , wherein the gel-forming polymer is present in an amount of about 3 to about 40 wt % of the composition.
48 . The therapeutic pharmaceutical composition of claim 41 , wherein the disintegrant is selected from the group consisting of sodium starch glycolate, crospovidone, and croscarmellose sodium.
49 . The therapeutic pharmaceutical composition of claim 41 , wherein the gel forming polymer is present in an amount of 3.8 to 39 wt %.
50 . The therapeutic pharmaceutical composition of claim 41 , wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.
51 . The therapeutic pharmaceutical composition of claim 47 , wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.
52 . The therapeutic pharmaceutical composition of claim 49 , wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.